Genmab A (GMAB) Gross Margin (2024 - 2026)

Genmab A has reported Gross Margin for 3 years, with the latest figure at 92.75% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 138.0% year-over-year to 92.75%; the trailing twelve-month figure through Mar 2026 stood at 93.76% (down 154.0% YoY), and the FY2025 full-year result was 93.6%, down 182.0% from the prior year.
• Gross Margin for Q1 2026 stood at 92.75%, down from 94.32% in the prior quarter.
• The five-year high for Gross Margin was 96.41% in Q2 2024, with the low at 92.75% in Q1 2026.
• Historically, Gross Margin has averaged 94.58% across 3 years, with a median of 94.32% in 2025.
• The largest YoY upside for Gross Margin was 77 bps in 2025 against a maximum downside of 257 bps in 2025.
• Genmab A's Gross Margin stood at 95.1% in 2024, then declined by 1 bps to 94.32% in 2025, then fell by 2 bps to 92.75% in 2026.
• The last three Gross Margin figures came in at 92.75% (Q1 2026), 94.32% (Q3 2025), and 93.84% (Q2 2025), per Business Quant data.